Simultaneous detection of CYP3A5 and MDR1 polymorphisms based on the SNaPshot assay

Clinical Biochemistry

Volumn 44, Issue 5-6, 2011, Pages 418-422

  Li, Liang ^a   Li, Chuan Jiang ^a   Zhang, Yan Jun ^b   Zheng, Lei ^a   Jiang, Hai Xia ^a   Si Tu, Bo ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

Author keywords

CYP3A5; Genotyping; MDR1; Sequencing; SNP

Indexed keywords

CYTOCHROME P450 3A5; GENOMIC DNA; MULTIDRUG RESISTANCE PROTEIN 1;

ACCURACY; ARTICLE; ASSAY; CAPILLARY ELECTROPHORESIS; CHINESE; COLOR; CONTROLLED STUDY; DNA SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; RELIABILITY; SNAPSHOT ASSAY; VALIDITY;

BASE SEQUENCE; CYTOCHROME P-450 CYP3A; DNA PRIMERS; HUMANS; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 79952766377     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.12.018     Document Type: Article

References (25)

1. Niwa T., Murayama N., Emoto C., Yamazaki H. Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5. Curr Drug Metab 2008, 9:20-33.
2. Zhou S.F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008, 38:802-832.
3. Haufroid V., Mourad M., Van Kerckhove V., Wawrzyniak J., De Meyer M., Eddour D.C., et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004, 14:147-154.
4. Tran A., Jullien V., Alexandre J., Rey E., Rabillon F., Girre V., et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006, 79:570-580.
5. Zhao Y., Zhai D., He H., Li T., Chen X., Ji H. Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort. Eur J Clin Pharmacol 2009, 65:579-584.
6. Solas C., Simon N., Drogoul M.P., Quaranta S., Frixon-Marin V., Bourgarel-Rey V., et al. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients. Br J Clin Pharmacol 2007, 64:353-362.
7. Xiang Q., Zhao X., Zhou Y., Duan J.L., Cui Y.M. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J Clin Pharmacol 2010, 50:659-666.
8. Gurney H., Wong M., Balleine R.L., Rivory L.P., McLachlan A.J., Hoskins J.M., et al. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther 2007, 82:33-40.
9. Xie H.G., Wood A.J., Kim R.B., Stein C.M., Wilkinson G.R. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004, 5:243-272.
10. Ambudkar S.V., Kimchi-Sarfaty C., Sauna Z.E., Gottesman M.M. P-glycoprotein: from genomics to mechanism. Oncogene 2003, 22:7468-7485.
11. Musuamba F.T., Mourad M., Haufroid V., Delattre I.K., Verbeeck R.K., Wallemacq P. Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study. Ther Drug Monit 2009, 31:734-742.
12. Bochud M., Bovet P., Burnier M., Eap C.B. CYP3A5 and ABCB1 genes and hypertension. Pharmacogenomics 2009, 10:477-487.
13. Fredericks S., Moreton M., MacPhee I.A., Mohamed M., Marlowe S., Jorga A., et al. Genotyping cytochrome P450 3A5 using the Light Cycler. Ann Clin Biochem 2005, 42:376-381.
14. Kinoshita E., Kinoshita-Kikuta E., Nakashima H., Koike T. Genotyping and mapping assay of single-nucleotide polymorphisms in CYP3A5 using DNA-binding zinc(II) complexes. Clin Biochem 2010, 43:302-306.
15. Aquilante C.L., Langaee T.Y., Anderson P.L., Zineh I., Fletcher C.V. Multiplex PCR-pyrosequencing assay for genotyping CYP3A5 polymorphisms. Clin Chim Acta 2006, 372:195-198.
16. Falzoi M., Mossa A., Congeddu E., Saba L., Pani L. Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry. Pharmacogenomics 2010, 11:559-571.
17. Chen B., Fang J., Zhang W., Jin Z., Yu Z., Cai W. Detection of C1236T, G2677T/A, and C3435T polymorphism of MDR1 by amplification refractory mutation system PCR. J Clin Lab Anal 2009, 23:110-116.
18. Song P., Li S., Meibohm B., Gaber A.O., Honaker M.R., Kotb M., et al. Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: MDR1 single nucleotide polymorphism genotyping assay. AAPS PharmSci 2002, 4:E29.
19. Yang B., Zhou G., Huang L.L. PCR-free MDR1 polymorphism identification by gold nanoparticle probes. Anal Bioanal Chem 2010, 397:1937-1945.
20. Sunder-Plassmann R., Rieger S., Endler G., Brunner M., Müller M., Mannhalter C. Simultaneous analysis of MDR1 C3435T, G2677T/A, and C1236T genotypes by multiplexed mutagenically separated PCR. Clin Chem Lab Med 2005, 43:192-194.
21. Nakamura T., Sakaeda T., Takahashi M., Hashimoto K., Gemma N., Moriya Y., et al. Simultaneous determination of single nucleotide polymorphisms of MDR1 genes by electrochemical DNA chip. Drug Metab Pharmacokinet 2005, 20:219-225.
22. Gwee P.C., Tang K., Chua J.M., Lee E.J., Chong S.S., Lee C.G. Simultaneous genotyping of seven single-nucleotide polymorphisms in the MDR1 gene by single-tube multiplex minisequencing. Clin Chem 2003, 49:672-676.
23. Huang D., Gui C., Yi S., Yang Q., Yang R., Mei K. Typing of 24 mtDNA SNPs in a Chinese population using SNaPshot minisequencing. J Huazhong Univ Sci Technolog Med Sci 2010, 30:291-298.
24. Hurst C.D., Zuiverloon T.C., Hafner C., Zwarthoff E.C., Knowles M.A. A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene. BMC Res Notes 2009, 2:66.
25. Bender K. SNaPshot for pharmacogenetics by minisequencing. Methods Mol Biol. 2005, 297:243-252.